Business
Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress
– Agios to Present New Patient-Reported Outcomes (PRO) Data from ACTIVATE Phase 3 Study of PYRUKYND® (mitapivat) in Adults with PK Deficiency Who Do Not
About this update from Agios Pharmaceuticals, Inc.
[{"type":"text","content":"– Agios to Present New Patient-Reported Outcomes (PRO) Data from ACTIVATE Phase 3 Study of PYRUKYND® (mitapivat) in Adults with PK Deficiency Who Do Not Receive Regular Transfusions – – Agios to Present New Clinical Data Demonstrating the Normalization of Hemoglobin Levels with Long-term Treatment of PYRUKYND® in Adults with PK Deficiency – – New Clinical Data from Investigator-Sponsored ESTIMATE Phase 2 Study of PYRUKYND® in Sickle Cell Disease to Be Presented – – Agios to Host Investor Webcast on June 13 at 8 a.m. ET – CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced that clinical and translational data will be presented at the European Hematology Association (EHA) Annual Congress, hosted virtually and in person in Vienna on June 9-12, 2022. The accepted abstracts are listed below and are available online on the EHA meeting library website. All presentations can be accessed on demand by registered meeting attendees on the EHA Virtual Congress platform on Friday, June 20. Agios-led Abstracts: Poster Presentations Title: Long-term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults With Non–transfusion-dependent Alpha- or Beta-thalassemiaSession date and time: Friday, June 10 at 16:30 - 17:45 CESTAbstract: P1522Presenting Author: Kevin H. M. Kuo, M.D., Division of Hematology, University of Toronto, Toronto, Canada Title: Comorbidities and Complications Across Genotypes in Adult Patients With Pyruvate Kinase Deficiency: Analysis From the Peak RegistrySession date and time: Friday, June 10 at 16:30 - 17:45 CESTAbstract: P1542Presenting Author: Andreas Glenthøj, M.D., Department of Hematology, Rigshospitalet Copenhagen, Denmark Title: Mitapivat Decreases the Need for Transfusions Secondary to Poorly Tolerated Anemia and Acute Events Compared to Placebo in Patients With Pyruvate Kinase Deficiency Who Are Not Regularly TransfusedSession date and time: Friday, June 10 at 16:30 - 17:45 CESTAbstract: P1543Presenting Author: Hanny Al-Samkari, M.D., Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States Title: Bone Mineral Density Remains Stable in Pyruvate Kinase Deficiency Patients Receiving Long-term ...